Digging Into Office of Prescription Drug Promotion Violation Letters

16 Jan 2012
Analysis

Derrick Gingery @dgingery derrick.gingery@informa.com

Executive Summary

Risk-related violations were the most popular and Tuesday and Thursday were the days letters were most often issued in 2011. FDA also continued its trend of issuing more letters directing violators to only stop using the questionable promotion, rather than also requiring new truthful ads be disseminated.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical United States Compliance

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS054108

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS054108

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Digging Into Office of Prescription Drug Promotion Violation Letters

Analysis

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert